Poster | 6th Internet World Congress for Biomedical Sciences |
Karen K. Szumlinski(1)
(1)Albany Medical College - Albany. United States
Contact address: |
Karen K. Szumlinski Albany Medical College Department of Pharmacology and Neuroscience MC 136 Albany New York 518 United States ratgirl@sprintmail.com |
[Neuroscience] |
[Pharmacology] |
[Psychiatry] |
The phenomenon of sensitization has been implicated in various aspects of drug addiction. As such, the present study determined the effects of a potential anti-addictive agent, 18-methoxycoronaridine (18-MC; 40 mg/kg, IP, 19 h earlier), on the expression of behavioural and neurochemical sensitization following the repeated administration of cocaine (COC; 5 once daily injections of 15 mg/kg, IP), morphine (MOR; 5, once daily injections of 20 mg/kg, IP) or saline. Compared to vehicle controls, 18-MC significantly enhanced the expression of COC-induced locomotion (0, 10, 20 and 40 mg/kg, IP) in chronic COC treated rats only. In both acute and chronic COC rats, 18-MC potentiated the stereotypy induced by higher COC doses (20 and 40 mg/kg, IP). 18-MC potentiated the acute locomotor response to MOR (0, 5, 10, 20, 30 mg/kg, IP) but blocked the expression of MOR-induced locomotor sensitization in chronic MOR rats. Interestingly, 18-MC completely abolished the sensitized dopamine (DA) response in the nucleus accumbens (NAC) to COC (20 mg/kg), without altering the DA response of acute COC rats. In MOR rats, 18-MC also abolished the sensitized DA response in the NAC to MOR (20 mg/kg), a finding consistent with previous reports for acute MOR rats. From the present findings, it is concluded that the effects of 18-MC on the expression of drug-induced motor behaviour can be dissociated from the effects of this compound on drug self-administration. As the present findings for DA sensitization are consistent with 18-MC´s anti-addictive efficacy, it is proposed that 18-MC exerts its anti-addictive effects via a reversal of the neuroadapations mediating increased incentive salience for drugs of abuse in chronic drug users.
[Neuroscience] |
[Pharmacology] |
[Psychiatry] |